Discovery of the importance of the PI3K-AKT-mTOR intracellular pathway in the etiology of PIK3CA-related overgrowth syndromes has led to increased recognition of a spectrum of clinical phenotypes and the possibility of targeted therapy through PI3K-α inhibition. The gene discussed is MTOR; the disease is overgrowth syndrome.